British concern enters the Polish clinical research market via takeover

The Wrocław based company operates in the same sector as SCM. The deal was worth GBP 2.25 million. The investment was another step towards implementing Synexus' strategy of entering emerging markets like Poland. "We believe that acquiring SCM will be a meaningful step towards expansion in that part of Europe," said Michael Fort, Synexus president. The British company has commissioned contracts for world giants such as Novartis, AstraZeneca and GSK. Experts believe that Poland's clinical research market will develop very fast during the next few years. "I know at least 12 companies engaged in clinical research in Poland commissioned by pharmaceutical companies. This is a rapidly developing sector, but you have to know how to benefit from the interest in this country. We already face competition from countries like Russia," explained Tadeusz Pietrucha, the head of Biotech Consulting. (Puls Biznesu, p. 5) D.W.